11,657 Shares in Boston Scientific Corporation $BSX Purchased by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. purchased a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the second quarter, HoldingsChannel reports. The firm purchased 11,657 shares of the medical equipment provider’s stock, valued at approximately $498,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Renaissance Group LLC bought a new position in shares of Boston Scientific in the fourth quarter valued at about $28,064,000. Perigon Wealth Management LLC bought a new stake in shares of Boston Scientific during the 2nd quarter worth about $883,000. Y Intercept Hong Kong Ltd grew its stake in Boston Scientific by 148.8% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock valued at $47,816,000 after buying an additional 670,060 shares during the last quarter. PensionDanmark Pensionsforsikringsaktieselskab grew its stake in Boston Scientific by 9.9% in the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock valued at $13,659,000 after buying an additional 28,961 shares during the last quarter. Finally, Meiji Yasuda America Inc bought a new position in Boston Scientific in the 4th quarter valued at about $4,708,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $49.47 on Friday. Boston Scientific Corporation has a 12-month low of $42.20 and a 12-month high of $109.50. The company’s 50 day moving average price is $46.26 and its two-hundred day moving average price is $57.91. The firm has a market cap of $71.69 billion, a PE ratio of 20.03, a PEG ratio of 1.13 and a beta of 0.56. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its board has approved a stock repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s leadership believes its shares are undervalued.

Insiders Place Their Bets

In related news, Director David C. Habiger acquired 2,100 shares of the company’s stock in a transaction on Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the acquisition, the director directly owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael F. Mahoney bought 186,240 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were bought at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the transaction, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 194,522 shares of company stock worth $9,385,210 in the last 90 days. Company insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on BSX. Evercore set a $65.00 price objective on shares of Boston Scientific in a research report on Monday, July 6th. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Wolfe Research lowered Boston Scientific from an “outperform” rating to a “peer perform” rating in a research note on Friday, May 29th. Canaccord Genuity Group dropped their price target on Boston Scientific from $70.00 to $66.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Finally, Raymond James Financial restated an “outperform” rating and issued a $57.00 price target on shares of Boston Scientific in a research note on Thursday, July 30th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.